Overview

Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.

Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The purpose of the study was to assess the safety, immunogenicity, and clinical efficacy of adalimumab compared with placebo (during double-blind phase) and to to evaluate the long-term safety and maintenance of efficacy following repeated administration of adalimumab (during open-label extension phase) in patients with persistently active rheumatoid arthritis who were receiving concurrent methotrexate therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Abbott
Treatments:
Adalimumab
Methotrexate